文献速递类风湿关节炎

四种生物制剂治疗类风湿关节炎的疾病缓解与对氧磷酶-1活性及氧化脂质改善相关

Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins.
PubMed 文献 · RMD Open · 2024-10-26

在1213例中高疾病活动度的类风湿关节炎患者中,启动托珠单抗、阿巴西普、肿瘤坏死因子抑制剂或利妥昔单抗治疗6个月后,对氧磷酶-1活性总体升高,以托珠单抗组升高最明显且最一致;对氧磷酶-1三个结构域活性升高与DAS28-CRP/CDAI疾病活动度显著下降相关,内酯酶/芳基酯酶活性升高与ACR20/50/70应答显著相关。部分氧化脂质包括12-羟基二十碳四烯酸与疾病活动度指标相关。

要点

  • 启动生物制剂6个月后对氧磷酶-1活性总体升高,托珠单抗组升高最明显且最一致。
  • 对氧磷酶-1三个结构域活性升高与DAS28-CRP/CDAI疾病活动度显著下降相关(p<0.05)。
  • 内酯酶/芳基酯酶活性升高与ACR20/50/70应答显著相关,OR分别为1.12(95%CI 1.04, 1.22)和1.13(95%CI 1.04, 1.23),p<0.01。

核心结论

  • 在四种生物制剂类别中,疾病活动度改善与对氧磷酶-1活性增强相关,这对心血管安全性具有重要意义。

研究设计与样本

  • 研究为比较 effectiveness 注册研究(Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory CoNditions)队列研究,纳入1213例中高疾病活动度(CDAI>10)的成年类风湿关节炎患者。
  • 患者启动新生物制剂:托珠单抗 n=296、阿巴西普 n=374、肿瘤坏死因子抑制剂 n=427、利妥昔单抗 n=116,前瞻性随访。
  • 基线和生物制剂治疗6个月后检测血清对氧磷酶-1活性(芳基酯酶、内酯酶和PON assay)。
  • 在每组6个月DAS28-CRP应答最低和最高的患者子集中,用液相色谱-串联质谱法检测靶向氧化脂质 panel。

主要发现

  • 整个队列启动新生物制剂治疗6个月后对氧磷酶-1活性总体升高,托珠单抗组升高最明显且最一致。
  • 对氧磷酶-1三个结构域活性升高与DAS28-CRP/CDAI疾病活动度显著下降相关(p<0.05)。
  • 内酯酶/芳基酯酶活性升高与ACR20/50/70应答显著相关,OR分别为1.12(95%CI 1.04, 1.22)和1.13(95%CI 1.04, 1.23),p<0.01。
  • 部分氧化脂质包括12-羟基二十碳四烯酸与类风湿关节炎疾病活动度指标相关。

关键数值与推荐

  • 内酯酶/芳基酯酶活性升高与ACR20/50/70应答的OR分别为1.12(95%CI 1.04, 1.22)和1.13(95%CI 1.04, 1.23),p<0.01。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Paraoxonase-1 (PON1) is a high-density lipoprotein (HDL)-associated enzyme, that has been implicated as a biomarker of cardiovascular risk in patients with rheumatoid arthritis (RA). We aimed to investigate how different biologic therapies affect levels of PON1 and oxylipins. METHODS: 1213 adult patients with RA in the Comparative Effectiveness Registry to study Therapies for Arthritis and Inflammatory CoNditions cohort study with moderate-to-high disease activity (Clinical Disease Activity Index (CDAI) >10) who initiated a new biologic (tocilizumab (TCZ), n=296; abatacept, n=374; tumour necrosis factor inhibitors, n=427; rituximab, n=116) were followed prospectively with serum specimens analysed for PON1 activity by arylesterase (ARYL), lactonase (LAC) and PON assays at baseline and after 6 months of biologic therapy. A targeted panel of oxylipins was evaluated by liquid chromatography-mass spectrometry/mass spectrometry in a subset of patients with the lowest and highest 6-month Disease Activity Score 28 (DAS28)-C reactive protein (CRP) responses in each treatment group. RESULTS: PON1 activity generally increased in the entire cohort after 6 months of new biologic therapy, showing the greatest, most consistent increases in the TCZ group. Increases in all three PON1 domains associated with significant decreases in disease activity in DAS28-CRP/CDAI (p<0.05), and increases in LAC/ARYL were significantly associated with the American College of Rheumatology 20/50/70 responses (OR (95% CI) of 1.12 (1.04, 1.22) and 1.13 (1.04, 1.23), p<0.01, respectively), after controlling for other RA disease characteristics. Some oxylipins, including 12-hydroxyeicosatetraenoic acid correlated with RA disease activity measures. CONCLUSION: Improvement in disease activity across four classes of biologics is associated with enhanced PON1 activity, which has significant implications for cardiovascular safety.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Razmjou AA, Kremer JM, Pappas DA, et al. Disease response in rheumatoid arthritis across four biologic therapies associates with improvement in paraoxonase-1 activity and oxylipins. RMD Open. 2024. PMID: 39461874. doi:10.1136/rmdopen-2024-004829

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。